A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

August 30, 2025

Study Completion Date

November 30, 2025

Conditions
Atrial Fibrillation
Interventions
DRUG

HBI-3000

Small molecule, multi-ion channel blocker

DRUG

Placebo

Normal saline

Trial Locations (14)

3240

Waikato Hospital, Hamilton

6021

Wellington Regional Hospital, Wellington

11000

University Clinical Center of Serbia, Belgrade

11040

Dedinje Institute for Cardiovascular Diseases, Belgrade

11080

University Hospital Medical Center Bezanijska kosa, Belgrade

18108

Niš University Clinical Center, Niš

34102

NCH Research Institute, Naples

38801

North Mississippi Medical Center, Tupelo

62701

Prairie Education & Research, Springfield

75701

CHRISTUS Trinity Mother Frances Hospital - Tyler, Tyler

78000

University Clinical Center of the Republic of Srpska, Banja Luka

H1T 1C8

Montreal Heart Institute, Montreal

H2X 0C1

Centre hospitalier de L'Universite de Montral (CHUM), Montreal

J6V 2H2

Centre integre de sante et de services sociaux de Lanaudiere - Hopital Pierre-Le Gardeur, Terrebonne

All Listed Sponsors
lead

HUYABIO International, LLC.

INDUSTRY